TNFSF13B and systemic lupus erythematosus: Similarly, the rise in serum BAFF 4–8 weeks after rituximab treatment (at randomization) in the BEAT-lupus trial was associated with an increase in serum IgA2 anti-dsDNA antibody levels at 24 weeks (p = 0.041).